Table 1.
Cohort | Total no. of cells injected per mouse | No. of CD34+ cells injected per mouse | No. of HSPC injected per mouse | Mean no. of human CD45+ cells/μl | Mean no. of human CD4+ cells/μl | No. of TCID50 inoculateda (JR-CSF) | No. of viremic mice/no. of mice in cohort (%) | No. of viremic mice with no HSPC injected/no. of mice in cohort (%) |
---|---|---|---|---|---|---|---|---|
BLT-1010 | 6.5 × 105 | 4.7 × 105 | 4,900 | 532 | 138 | 1.4 × 106 | 6/8 (75) | 0/5 (0) |
BLT-1011 | 5.0 × 105 | 4.3 × 105 | 8,700 | 2,142 | 257 | 0.8 × 106 | 14/15 (93) | 3/5 (60) |
BLT-1012b | 3.3 × 105 | 2.7 × 105 | 2,500 | 1,785 | 261 | 1.1 × 106 | 14/16 (88) | 2/5 (40) |
BLT-1013 | 4.4 × 105 | 2.7 × 105 | 350 | 324 | 94 | 1.1 × 106 | 7/15 (47) | 0/5 (0) |
BLT-1014 | 2.0 × 105 | 1.6 × 105 | 1,400 | 520 | 100 | 1.0 × 106 | 5/7 (71) | 1/5 (20) |
BLT-1015 | 3.4 × 105 | 1.5 × 105 | 1,100 | 266 | 9 | 0.02 × 106 | 2/10 (20) | 0/2 (0) |
BLT-1016 | 1.5 × 105 | 1.3 × 105 | 620 | 308 | 10 | 0.4 × 106 | 3/8 (38) | 0/2 (0) |
BLT-1017 | 3.7 × 105 | 2.6 × 105 | 910 | 1,141 | 148 | 0.03 × 106 | 4/8 (50) | NDc |
BLT-1018 | 7.5 × 105 | 6.0 × 105 | 760 | 1,195 | 43 | 0.02 × 106 | 2/9 (22) | NDc |
BLT-1020 | 4.4 × 105 | 2.3 × 105 | 150 | 349 | 129 | 3.7 × 106 | 1/8 (13) | 0/5 (0) |
BLT-1021 | 1.8 × 105 | 1.6 × 105 | 1,900 | 577 | 317 | 4.5 × 106 | 13/14 (93) | 5/5 (100) |
BLT-1022 | 11.0 × 105 | 8.8 × 105 | 5,800 | 1,479 | 140 | 3.0 × 106 | 5/9 (56) | 0/5 (0) |
BLT-1023 | 2.9 × 105 | 2.4 × 105 | 820 | 747 | 188 | 0.5 × 106 | 3/5 (60) | 0/5 (0) |
BLT-1101 | 3.0 × 105 | 2.2 × 105 | 1,100 | 339 | 82 | 0.5 × 106 | 0/5 (0) | 0/5 (0) |
Assessed by limiting dilution assay in phytohemagglutinin-activated peripheral blood mononuclear cells with supernatant p24 detection 7 days after inoculation.
CCR5 Δ32+/− cohort susceptible to HIV JR-CSF infection.
ND, not determined.